“Prospects are good for companies aiming to develop products for animals because people are willing to spend more money to ensure that their pets are healthy.”
Stockhouse talks to Bob Weir, President and Chief Executive Officer of eResearch Corp. in Toronto.
Focus: Providing equity research on small cap biotech and mining companies
Can you give me your perspective on what is happening in the market right now?
“Like junior mining companies, small cap biotech firms need to continually come back to the market to raise funds for research and development. Prospects are good for companies aiming to develop products for animal care because people are willing to spend more money to ensure that their pets are healthy.”
What is your take on Ottawa company Chemaphor Inc.?
“We think that this company has incredible potential.’’ On April 19, Chemaphor (TSX: V.CFR, Stock Forum) announced that it has received its first order for Oximunol Chewables for the veterinary market in the U.S. Oximunol chewables contain the active ingredient OxC-beta, which works with a dog’s immune system to optimize the animal’s overall health and wellbeing. “Chemaphor has some sales in Canada. But this first U.S. order for Oximunol will attract a lot of attention in the U.S.”
Trading at 8 cents this week, Chemaphor has a market cap of $6.7 million, based on 83.8 million shares outstanding. The 52-week range is 15 cents and 4 cents.
Are there any other companies that you are watching in this space?
Bioniche Life Sciences Inc. (TSX: T. BNC, Stock Forum) is a Belleville, Ont.-based pharmaceutical company and developer of products for animal and human health. “The company has developed an anti-cancer bladder product that is expected to be on the market by 2015.” Trading at 54 cents this week, Bioniche has a market cap of $55.7 million, based on 103.2 million shares outstanding. The 52-week range is $1.26 and 47 cents.